Effectiveness of emicizumab in preventing life-threatening bleeding complications in type 3 von Willebrand disease with inhibitors: A paediatric report

被引：15
|
作者：
Cefalo, Maria Giuseppina [1 ,2 ]
Ronco, Francesca [1 ,2 ]
Di Felice, Giovina [1 ,2 ]
Rinelli, Martina [1 ,2 ]
Oriana, Vincenzo [1 ,2 ]
Massoud, Michela [1 ,2 ]
Merli, Pietro [1 ,2 ]
Luciani, Matteo [1 ,2 ]
机构：
[1] Bambino Gesu Pediat Hosp, Rome, Italy
[2] Azienda Osped Bianchi Melacrino Morelli, Reggio Di Calabria, Italy
来源：
HAEMOPHILIA | 2021年 / 27卷 / 04期
关键词：
bleeding disorders; childhood; emicizumab; factor VIII deficiency; inhibitors; von Willebrand disease; ALLOANTIBODIES; DELETIONS; EFFICACY;
D O I：
10.1111/hae.14209
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E495 / E497
页数：3
相关论文
共 22 条
  • [1] Emicizumab in Type 3 von Willebrand Disease: Report of a Case with an Alloantibody and Literature Review
    Giuffrida, Anna C.
    Siboni, Simona M.
    Baronciani, Luciano
    Poli, Giovanni
    Gandini, Giorgio
    Peyvandi, Flora
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2025, 51 (01) : 73 - 80
  • [2] Life-threatening bleeding in a patient with mild hemophilia A and heterozygosity for von Willebrand disease Type 2N
    John N. Allan
    Kenneth D. Friedman
    Maria T. DeSancho
    International Journal of Hematology, 2014, 100 : 602 - 606
  • [3] Life-threatening bleeding in a patient with mild hemophilia A and heterozygosity for von Willebrand disease Type 2N
    Allan, John N.
    Friedman, Kenneth D.
    DeSancho, Maria T.
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 100 (06) : 602 - 606
  • [4] Bleeding management in type 3 von Willebrand disease with anti-von Willebrand factor inhibitor: A literature review and case report
    Briane, Aurelie
    Horvais, Valerie
    Sigaud, Marianne
    Trossaert, Marc
    Drillaud, Nicolas
    Ternisien, Catherine
    Fouassier, Marc
    Babuty, Antoine
    EJHAEM, 2024, 5 (05): : 964 - 970
  • [5] Improved prevention of bleeding episodes with emicizumab in 3 patients with concomitant hemophilia A and von Willebrand disease
    Ansteatt, Kristin T.
    Roberts, Jonathan C.
    Helms, Jackie M.
    Tarantino, Michael D.
    BLOOD COAGULATION & FIBRINOLYSIS, 2024, 35 (07) : 340 - 344
  • [6] Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3
    Berntorp, Erik
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 (06) : 621 - 625
  • [7] Efficacy of emicizumab therapy in two adult patients with type 3 von Willebrand disease
    LeMaistre, Frederick Ian
    Chiang, Elaine
    Streiff, Michael B.
    Yui, Jennifer C.
    BLOOD COAGULATION & FIBRINOLYSIS, 2024, 35 (04) : 206 - 208
  • [8] Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies
    Weyand, Angela C.
    Flood, Veronica H.
    Shavit, Jordan A.
    Pipe, Steven W.
    BLOOD ADVANCES, 2019, 3 (18) : 2748 - 2750
  • [9] Monitoring of von Willebrand factor inhibitors in patients with type 3 von Willebrand disease using a quantitative assay
    Miller, Connie H.
    HAEMOPHILIA, 2021, 27 (05) : 823 - 829
  • [10] Type 3 von Willebrand disease with inhibitors (VWD3i) - haemostatic control and transfusional complications
    Camara, Catarina
    Felix, Jorge
    Rodrigues, Fatima
    Pereira, Artur
    Catarino, Cristina
    HAEMOPHILIA, 2024, 30 : 79 - 79
123